<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Potential New Standard for High-Risk, Pediatric B-Cell Lymphoma

Default sub title

minute read

by MedPage Today | June 1, 2020
placeholder

Adding rituximab (Rituxan) to standard lymphomes malins B (LMB) chemotherapy in children and adolescents with high-risk, mature B-cell lymphoma significantly improved event-free and overall survival, an international phase III trial showed.

Topics: Press Coverage